Brentuximab Vedotin (Solution) provides a CD30-targeting antibody-drug conjugate (ADC) in solution form for lymphoma and oncology research. It combines a CD30-directed monoclonal antibody with monomethyl auristatin E (MMAE), a potent microtubule-disrupting payload and specifically supports studies of targeted cytotoxicity, Hodgkin lymphoma, and antibody-mediated drug delivery.
Key Features and Benefits
- CD30-Targeting ADC: Combines a CD30-directed monoclonal antibody with the cytotoxic MMAE payload for targeted lymphoma research.
- MMAE Payload: Contains monomethyl auristatin E, a potent microtubule inhibitor specifically studied in ADC research.
- CD30 Recognition: Supports investigation of CD30 expression, antibody binding, internalization, and lymphoma cell targeting.
- Cleavable Linker: Uses a protease-cleavable valine-citrulline linker specifically designed to facilitate intracellular MMAE release.
- Targeted Payload Delivery: Supports investigation of antibody-mediated MMAE delivery to CD30-expressing cancer cells.
- Microtubule Disruption: MMAE inhibits microtubule polymerization, supporting studies of cell-cycle arrest and ADC-mediated cytotoxicity.
- Bystander Cytotoxicity: The membrane-permeable MMAE payload specifically supports investigation of cytotoxic effects on neighboring tumor cells.
- Solution Formulation: Provides the ADC in solution form specifically for research workflows requiring a liquid preparation.
Applications
- Hodgkin Lymphoma Research: Supports investigation of CD30-targeted ADC mechanisms in classical Hodgkin lymphoma models.
- Anaplastic Large Cell Lymphoma Research: Useful for studying ADC-mediated cytotoxicity in CD30-positive anaplastic large cell lymphoma models.
- CD30-Positive Lymphoma Research: Supports studies of antibody targeting and cytotoxic responses in CD30-expressing lymphoma cells.
- T-Cell Lymphoma Research: Useful for investigating CD30-directed ADC strategies in relevant T-cell lymphoma models.
- ADC Research: Supports studies of antibody binding, internalization, intracellular processing, and payload release.
- Targeted Cancer Research: Enables investigation of antibody-mediated MMAE delivery to CD30-expressing cancer cells.
- Cell-Based Lymphoma Assays: Useful for evaluating CD30-dependent binding, cellular uptake, cytotoxicity, and apoptosis.
- Mechanism-of-Action Studies: Supports investigation of CD30 targeting and MMAE-mediated microtubule disruption.
- Comparative ADC Research: Useful for comparing CD30-directed ADCs, cleavable linker systems, and auristatin payloads.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect the solution from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve antibody stability, conjugate integrity, and solution quality.
Brentuximab Vedotin (Solution) combines CD30-directed antibody targeting with the microtubule-disrupting MMAE payload and specifically supports Hodgkin lymphoma, anaplastic large cell lymphoma, CD30-positive cancer, ADC, and targeted drug delivery research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
